CYTO Altamira Therapeutics Ltd

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 2023

 

Commission File Number: 001-36582

 

Altamira Therapeutics Ltd.

(Exact name of registrant as specified in its charter)

 

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ☐     No ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ☐     No ☒

 

 

 

Loan Agreements

 

On December 28, 2022, Altamira Therapeutics Ltd. (the “Company”) entered into two loan agreements with separate private investors (the “Private Lenders”), pursuant to which the Private Lenders loaned the Company an aggregate of CHF 350,000.00 (the “December 2022 Loan Agreements”), collectively, which loans bear interest at the rate of 5% per annum and mature as of May 30, 2023. The Company agreed to grant to the Private Lenders warrants to purchase an aggregate of 47,180 of the Company’s common shares. Such warrants will be exercisable immediately at an exercise price of CHF 4.4512 per share, may be exercised up to five years from the date of issuance and may be exercised on a cashless basis in certain circumstances specified therein. The December 2022 Loan Agreements and related warrants used the same form of agreement and warrant as the previously disclosed loan agreement dated September 9, 2022, among the Company, FiveT Investment Management Ltd., Dominik Lysek and Thomas Meyer, the Company’s CEO, and related warrants, other than the applicable principal amount, maturity date and warrant exercise price and amount.

 

FiveT Loan Amendment

 

On February 4, 2022, the Company entered into a convertible loan agreement (the “FiveT Loan”) with FiveT Investment Management Ltd., or FiveT IM, an affiliate of FiveT Capital Holding Ltd., or FiveT, pursuant to which FiveT IM agreed to loan to the Company CHF 5,000,000, which loan bears interest at the rate of 10% per annum. On January 26, 2023, the Company and FiveT IM entered into an amendment to the FiveT Loan (the “FiveT Loan Amendment”), which amendment (i) extends the maturity date of the FiveT Loan to March 15, 2023; (ii) provides that the Company may repay amounts owed under the FiveT Loan prior to maturity with no penalty or premium; (iii) provides that in the event of a public or private offering (a “Qualifying Offering”) by the Company of common shares (other than through an equity line or at-the-market program), the Company will make a partial repayment, upon the closing of the offering, of the principal amount of the FiveT Loan comprised of (A) $1,000,000 in cash and (B) newly issued common shares in an amount equaling 9.9% of the total outstanding common shares post-issuance and after giving effect to such offering, with such common shares being valued for purposes of such repayment at the offering price per common share in such offering (the “Qualifying Offering Price”); and (iv) provides that upon the closing of such offering, assuming the Company has sufficient authorized and unissued common shares, the Company shall have the option to cause FiveT IM to convert the remaining outstanding amount of the FiveT Loan after the repayment described in (iii) above into a pre-funded warrant (the “Pre-Funded Warrant”), having an exercise price of CHF 0.01 per common share, giving FiveT IM the right to purchase a number of common shares equal to (A) the total remaining outstanding amount of the FiveT Loan divided by (B) the Qualifying Offering Price less CHF 0.01. The Pre-Funded Warrants will provide that until February 21, 2024, FiveT IM may cause the Company to redeem for cash all or portions of the Pre-Funded Warrant using up to 40% of the cash proceeds from certain out-licensing or divestiture transactions to the extent completed by the Company, with the amount of the Pre-Funded Warrant being redeemed equal to (A) the desired redemption amount divided by (B) the Qualifying Offering Price less CHF 0.01.

 

Special General Meeting of Shareholders

 

The Board of Directors of Altamira Therapeutics Ltd. has decided to call a Special General Meeting of Shareholders (“Special General Meeting”) in order to propose an increase in the authorized share capital of the Company from CHF 1,400,000 divided into 5,000,000 common shares of CHF 0.20 each and 20,000,000 preference shares of CHF 0.02 each to CHF 5,400,000 divided into 25,000,000 common shares of CHF 0.20 each and 20,000,000 preference shares of CHF 0.02 each, by the creation of an additional 20,000,000 common shares of CHF 0.20 each ranking pari-passu with the existing common shares of the Company. The proposed modification of the amount of the authorized share capital shall increase the Company’s flexibility for corporate finance purposes and does not imply or constitute any immediate increase in the amount of shares outstanding.

 

The Special General Meeting will be held on February 17, 2023, 8:30 AM local Bermuda time at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.

 

 

INCORPORATION BY REFERENCE

 

This Report on Form 6-K, including the exhibits to this Report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-228121, 333-249347, 333-261127 and 333-264298) and Form S-8 (Registration Numbers 333-232735 and 333-252141) of Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Altamira Therapeutics Ltd.
Date: January 27, 2023	By:	/s/ Thomas Meyer
		Name:	Thomas Meyer
		Title:	Chief Executive Officer

 

3

 

 

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Amendment No. 1 to Convertible Loan Agreement, dated January 26, 2023, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd.
99.2		Form of Pre-Funded Warrant
99.3		Notice to Shareholders dated January 27, 2023
99.4		Proxy Card for the Special General Meeting of Shareholders
99.5		Press Release, dated January 27, 2023

 

 

4